Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially regarding the cross-talk between PPAR-γ and other potent fibrogenic factors. Methods: This experimental study involved 25 male Wistar rats. Twenty rats were subjected to bile duct ligation (BDL) to induce liver fibrosis, further divided into an untreated group (BDL; n=10) and a group treated with the PPAR-γ agonist thiazolidinedione (TZD), at 14 days post-operation (BDL+TZD; n=10). The remaining 5 rats had a sham operation (sham; n=5). The effect of PPAR-γ agonist on liver fibrosis was evaluated by histopathology, protein immunohistochemistry, and mRNA expression quantitative polymerase chain reaction. Results: Histology and immunostaining showed markedly reduced collagen deposition, bile duct proliferation, and HSCs in the BDL+TZD group compared to those in the BDL group (p<0.001). Similarly, significantly lower mRNA expression of collagen α-1(I), matrix metalloproteinase-2, platelet-derived growth factor (PDGF)-B chain, and connective tissue growth factor (CTGF) were evident in the BDL+TZD group compared to those in the BDL group (p=0.0002, p<0.035, p<0.0001, and p=0.0123 respectively). Moreover, expression of the transforming growth factor beta1 (TGF-β1) was also downregulated in the BDL+TZD group (p=0.0087). Conclusion: The PPAR-γ agonist inhibits HSC activation in vivo and attenuates liver fibrosis through several fibrogenic pathways. Potent fibrogenic factors such as PDGF, CTGF, and TGF-β1 were downregulated by the PPAR-γ agonist. Targeting PPAR-γ activity may be a potential strategy to control liver fibrosis.
Abstract
Purpose: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a key role in hepatic fibrogenesis by virtue of its effect on the hepatic stellate cells (HSCs). Although many studies have shown that PPAR-γ agonists inhibit liver fibrosis, the mechanism remains largely unclear, especially regarding the cross-talk between PPAR-γ and other potent fibrogenic factors. Methods: This experimental study involved 25 male Wistar rats. Twenty rats were subjected to bile duct ligation (BDL) to induce liver fibrosis, further divided into an untreated group (BDL; n=10) and a group treated with the PPAR-γ agonist thiazolidinedione (TZD), at 14 days post-operation (BDL+TZD; n=10). The remaining 5 rats had a sham operation (sham; n=5). The effect of PPAR-γ agonist on liver fibrosis was evaluated by histopathology, protein immunohistochemistry, and mRNA expression quantitative polymerase chain reaction. Results: Histology and immunostaining showed markedly reduced collagen deposition, bile duct proliferation, and HSCs in the BDL+TZD group compared to those in the BDL group (p<0.001). Similarly, significantly lower mRNA expression of collagen α-1(I), matrix metalloproteinase-2, platelet-derived growth factor (PDGF)-B chain, and connective tissue growth factor (CTGF) were evident in the BDL+TZD group compared to those in the BDL group (p=0.0002, p<0.035, p<0.0001, and p=0.0123 respectively). Moreover, expression of the transforming growth factor beta1 (TGF-β1) was also downregulated in the BDL+TZD group (p=0.0087). Conclusion: The PPAR-γ agonist inhibits HSC activation in vivo and attenuates liver fibrosis through several fibrogenic pathways. Potent fibrogenic factors such as PDGF, CTGF, and TGF-β1 were downregulated by the PPAR-γ agonist. Targeting PPAR-γ activity may be a potential strategy to control liver fibrosis.
참고문헌 (26)
- Iwaisako K, "Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist", Proc Natl Acad Sci U S A, 109, pp.E1369~1376 (2012)
- Popov Y, "Targeting liver fibrosis : strategies for development and validation of antifibrotic therapies", Hepatology, 50, pp.1294~1306 (2009)
- Thompson AJ, "Antifibrotic therapies : will we ever get there", Curr Gastroenterol Rep, 12, pp.23~29 (2010)
- Moreira RK, "Hepatic stellate cells and liver fibrosis", Arch Pathol Lab Med, 131, pp.1728~1734 (2007)
- Rockey DC, "Current and future anti-fibrotic therapies for chronic liver disease", Clin Liver Dis, 12, pp.939~962 (2008)
- Marra F, "Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells", Gastroenterology, 119, pp.466~478 (2000)
- Wei J, "Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ : a novel link between metabolism and fibrogenesis", Open Rheumatol J, 6, pp.103~115 (2012)
- Wang Z, "Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats", Hepatobiliary Pancreat Dis Int, 10, pp.64~71 (2011)
- Fiorucci S, "Cross-talk between farnesoid-X-receptor(FXR)and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis", J Pharmacol Exp Ther, 315, pp.58~68 (2005)
- 배명애, "Selective Inhibition of Activated Stellate Cells and Protection from Carbon Tetrachloride-Induced Liver Injury in Rats by a New PPARγ agonist KR62776", Archives of Pharmacal Research, 33(3), pp.433~442 (2010), 대한약학회
- Zhang F, "Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis", Cell Signal, 24, pp.596~605 (2012)
- Zhao C, "PPARgamma agonists prevent TGFbeta1", Smad3-signaling in human hepatic stellate cells, 2006, pp.350, 385~391
- Alatas FS, "Synchronized expressions of hepatic stellate cells and their transactivation and liver regeneration during liver injury in an animal model of cholestasis", J Pediatr Surg, 46, pp.2284~2290 (2011)
- Gressner OA, "Connective tissue growth factor : a fibrogenic master switch in fibrotic liver diseases", Liver Int, 28, pp.1065~1079 (2008)
- Troeger JS, "Deactivation of hepatic stellate cells during liver fibrosis resolution in mice", Gastroenterology, 143, pp.1073~1083 (2012)
- Bataller R, "Liver fibrosis", J Clin Invest, 115, pp.209~218 (2005)
- Reynaert H, "Review article : the treatment of non-alcoholic steatohepatitis with thiazolidinediones", Aliment Pharmacol Ther, 22, pp.897~905 (2005)
- Hazra S, "PPAR Gamma and Hepatic Stellate Cells", Comp Hepatol, 3(Suppl 1), pp.S7~ (2004)
- She H, "Adipogenic transcriptional regulation of hepatic stellate cells", J Biol Chem, 280, pp.4959~4967 (2005)
- Yang L, "Effectiveness of the PPARγ agonist, GW570, in liver fibrosis", Inflamm Res, 59, pp.1061~1071 (2010)
- Miyahara T, "Peroxisome proliferator-activated receptors and hepatic stellate cell activation", J Biol Chem, 275, pp.35715~35722 (2000)
- Galli A, "Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro", Gastroenterology, 122, pp.1924~1940 (2002)
- Gressner AM, "Mediators of hepatic fibrogenesis", Hepatogastroenterology, 43, pp.92~103 (1996)
- Pinzani M, "Liver fibrosis : from the bench to clinical targets", Dig Liver Dis, 36, pp.231~242 (2004)
- Parsons CJ, "Molecular mechanisms of hepatic fibrogenesis", J Gastroenterol Hepatol, 22(Suppl 1), pp.S79~84 (2007)
- Huang G, "Regulation of hepatic stellate cells by connective tissue growth factor", Front Biosci(Landmark Ed), 17, pp.2495~2507 (2012)